Argenx Se Share Price (NASDAQ: ARGX)

$704.84

▲

-3.12

(-0.44%)

Last updated on August 29, 2025 at 1:29 am IST

$₹

Check the interactive Argenx Se Stock chart to analyse performance

Argenx Se stock performance

as on August 29, 2025 at 1:29 am IST

Today's Low:$698.69
Today's High:$704.84
$704.84
0.87%
Downside
Day's Volatility :0.87%
Upside
0.0%
52 Weeks Low:$510.06
52 Weeks High:$710.00
$704.84
27.64%
Downside
52 Weeks Volatility :28.16%
Upside
0.73%

Argenx Se Stock Returns

Period	Argenx Se	Sector (Health Care)	Index (Russel 2000)
3 Months	23.5%	4.2%	0.0%
6 Months	13.33%	-8.0%	0.0%
1 Year	36.76%	-12.1%	0.0%
3 Years	85.79%	7.6%	-6.9%

Argenx Se Key Stats

Check Argenx Se key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$707.96
Open	$698.69
Today's High	$704.84
Today's Low	$698.69
Market Capitalization	$43.3B
Today's Volume	$342.3K
52 Week High	$710.0
52 Week Low	$510.055
Revenue TTM	$3.1B
EBITDA	$469.0M
Earnings Per Share (EPS)	$19.68
PE Ratio	35.98
Profit Margin	41.03%
Quarterly Earnings Growth YOY	7.35%
Return On Equity TTM	24.72%

Stock Returns calculator for Argenx Se Stock including INR - Dollar returns

The Argenx Se stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Argenx Se investment value today

Current value as on today

₹1,40,715

Returns

₹40,715

(+40.72%)

Returns from Argenx Se Stock

₹36,159 (+36.16%)

Dollar Returns*

₹4,556 (+4.56%)

Indian investors sentiment towards Argenx Se Stock

84%

Period: Jul 29, 2025 to Aug 28, 2025. Change in 30 Days versus previous period

Search interest for Argenx Se Stock from India on INDmoney has increased by 84% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Argenx Se

Name
Holdings %
Name
Holdings %
FMR Inc
9.25%
T. Rowe Price Associates, Inc.
8.14%
HHG PLC
4.19%
Artisan Partners Limited Partnership
3.84%
Capital World Investors
3.19%
venBio Select Advisor LLC
1.92%

Analyst Recommendation on Argenx Se Stock

Rating

Trend

Buy

72%Buy

24%Hold

4%Sell

Based on 25 Wall street analysts offering stock ratings for Argenx Se(by analysts ranked 0 to 5 stars)

Argenx Se Share Price Target

What analysts predicted

Upside of 14.15%

Target:

$804.60

Current:

$704.84

Argenx Se share price target is $804.60, a slight Upside of 14.15% compared to current price of $704.84 as per analysts' prediction.

Argenx Se Stock Insights

Price Movement
In the last 1 month, ARGX stock has moved up by 18.9%
Increasing Revenue
Argenx SE has shown positive revenue growth over the last two quarters. In the most recent quarter, the revenue increased to $947.96 million, up from $790.68 million in the previous quarter. This reflects an average growth rate of 16.6% per quarter.
Increasing Net Profit
Argenx SE has shown strong profit growth over the last two quarters. Their net profit increased from $169.46 million to $245.35 million, which represents an average growth of 30.9% per quarter.
ARGX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 61.8% return, outperforming this stock by 25.4%
ARGX vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 115.3% return, outperforming this stock by 31.0%
Price to Sales
Argenx SE has a very high Price-to-Sales Ratio of $341.6, meaning investors are willing to pay $341.6 for every $1 of sales the company generates. In comparison, Alnylam Pharmaceuticals, Inc. has a much lower Price-to-Sales Ratio of $23.8, indicating that investors pay significantly less for each dollar of sales. This suggests that investors have high expectations for Argenx SE's future growth relative to its current sales.

Argenx Se Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$87.2M	↑ 219.3%
Net Income	$-201.4M	↑ 137.71%
Net Profit Margin	-230.95%	↑ 79.27%

	FY20	Y/Y Change
Revenue	$50.2M	↓ 47.44%
Net Income	$-740.1M	↑ 235.78%
Net Profit Margin	-1.5K%	↓ 1244.34%

	FY21	Y/Y Change
Revenue	$562.2M	↑ 1105.72%
Net Income	$-460.8M	↓ 33.01%
Net Profit Margin	-81.97%	↑ 1393.32%

	FY22	Y/Y Change
Revenue	$434.7M	↓ 17.4%
Net Income	$-750.9M	↑ 74.08%
Net Profit Margin	-172.76%	↓ 90.79%

	FY23	Y/Y Change
Revenue	$1.3B	↑ 198.56%
Net Income	$-321.9M	↓ 58.42%
Net Profit Margin	-24.06%	↑ 148.7%

	FY24	Y/Y Change
Revenue	$2.2B	↑ 78.6%
Net Income	$833.0M	↓ 382.34%
Net Profit Margin	38.03%	↑ 62.09%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$401.0M	↓ 41.57%
Net Income	$-61.6M	↓ 60.42%
Net Profit Margin	-15.36%	↑ 7.32%

	Q2 FY24	Q/Q Change
Revenue	$514.0M	↑ 19.11%
Net Income	$-32.7M	↓ 50.7%
Net Profit Margin	-6.36%	↑ 9.0%

	Q3 FY24	Q/Q Change
Revenue	$636.5M	↑ 20.02%
Net Income	$101.5M	↓ 401.01%
Net Profit Margin	15.95%	↑ 22.31%

	Q4 FY24	Q/Q Change
Revenue	$1.3B	↑ 134.85%
Net Income	$865.6M	↑ 846.91%
Net Profit Margin	64.29%	↑ 48.34%

	Q1 FY25	Q/Q Change
Revenue	$790.7M	↓ 41.27%
Net Income	$169.5M	↓ 80.42%
Net Profit Margin	21.43%	↓ 42.86%

	Q2 FY25	Q/Q Change
Revenue	$948.0M	↑ 19.89%
Net Income	$245.4M	↑ 44.78%
Net Profit Margin	25.88%	↑ 4.45%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$87.2M	↑ 219.3%

	FY20	Y/Y Change
Profit	$50.2M	↓ 47.44%

	FY21	Y/Y Change
Profit	$562.2M	↑ 1105.72%

	FY22	Y/Y Change
Profit	$403.5M	↓ 23.32%

	FY23	Y/Y Change
Profit	$1.2B	↑ 190.7%

	FY24	Y/Y Change
Profit	$2.0B	↑ 77.08%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$357.8M	↓ 2.6%

	Q2 FY24	Q/Q Change
Profit	$836.8M	↑ 117.33%

	Q3 FY24	Q/Q Change
Profit	$570.9M	↓ 33.88%

	Q4 FY24	Q/Q Change
Profit	$681.4M	↑ 32.52%

	Q1 FY25	Q/Q Change
Profit	$709.9M	↑ 4.18%

	Q2 FY25	Q/Q Change
Profit	$837.2M	↑ 17.94%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$168.5M	↓ 346.2%
Investing Cash Flow	$-926.0M	↑ 577.35%
Financing Cash Flow	$815.3M	↑ 162.16%

	FY20	Y/Y Change
Operating Cash Flow	$-484.7M	↓ 362.79%
Investing Cash Flow	$419.3M	↓ 141.37%
Financing Cash Flow	$1.0B	↑ 13.53%

	FY21	Y/Y Change
Operating Cash Flow	$-686.0M	↑ 52.29%
Investing Cash Flow	$-392.3M	↓ 200.69%
Financing Cash Flow	$1.3B	↑ 34.4%

	FY22	Y/Y Change
Operating Cash Flow	$-913.1M	↑ 42.19%
Investing Cash Flow	$-488.0M	↑ 32.88%
Financing Cash Flow	$892.9M	↓ 24.64%

	FY23	Y/Y Change
Operating Cash Flow	$-458.5M	↓ 51.28%
Investing Cash Flow	$336.2M	↓ 166.83%
Financing Cash Flow	$1.5B	↑ 58.43%

	FY24	Y/Y Change
Operating Cash Flow	$-82.7M	↓ 80.31%
Investing Cash Flow	$-717.6M	↓ 332.83%
Financing Cash Flow	$279.8M	↓ 79.07%

Q4 FY22

Q2 FY23

Q4 FY23

Q2 FY24

Q4 FY24

Q2 FY25

	Q4 FY22	Q/Q Change
Operating Cash Flow	$-364.0M	↓ 27.13%
Investing Cash Flow	$-226.2M	↓ 3.63%
Financing Cash Flow	$35.1M	↓ 95.7%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-280.4M	↓ 24.84%
Investing Cash Flow	$523.9M	↓ 325.98%
Financing Cash Flow	$61.9M	↑ 72.26%

	Q4 FY23	Q/Q Change
Operating Cash Flow	$-147.2M	↓ 47.82%
Investing Cash Flow	$-216.2M	↓ 141.04%
Financing Cash Flow	$1.3B	↑ 1922.37%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-134.1M	↓ 7.59%
Investing Cash Flow	$-516.1M	↑ 141.98%
Financing Cash Flow	$40.3M	↓ 96.76%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$41.9M	↓ 133.62%
Investing Cash Flow	$-203.8M	↓ 57.5%
Financing Cash Flow	$239.7M	↑ 540.71%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$437.9M	↑ 944.77%
Investing Cash Flow	$-10.3M	↓ 94.94%
Financing Cash Flow	$74.1M	↓ 69.09%

Argenx Se Technicals Summary

Sell

Neutral

Buy

Argenx Se is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Argenx Se Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Argenx Se	18.21%	13.33%	36.76%	85.79%	206.12%
Regeneron Pharmaceuticals, Inc.	5.16%	-16.0%	-50.21%	-0.24%	-5.32%
Beone Medicines Ltd	0.07%	10.43%	51.2%	81.32%	24.25%
Vertex Pharmaceuticals Incorporated	-16.94%	-18.91%	-21.14%	38.29%	39.4%
Alnylam Pharmaceuticals, Inc.	37.4%	84.06%	58.25%	116.31%	242.42%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Argenx Se	35.98	35.98	2.0	13.22	0.25	0.05	NA	99.66
Regeneron Pharmaceuticals, Inc.	14.86	14.86	1.21	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.58	27.58	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Argenx Se	Buy	$43.3B	206.12%	35.98	41.03%
Regeneron Pharmaceuticals, Inc.	Buy	$62.5B	-5.32%	14.86	31.37%
Beone Medicines Ltd	NA	$37.7B	24.25%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$99.3B	39.4%	27.58	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.1B	242.42%	NA	-12.96%

About Argenx Se

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Organization	Argenx Se
Employees	1599
CEO	Mr. Timothy Van Hauwermeiren EMBA, M.Sc.
Industry	Health Technology

Key Management of Argenx Se

Name	Title
Mr. Timothy Van Hauwermeiren EMBA, M.Sc.	Co-Founder, CEO & Executive Director
Mr. Karl Gubitz	Chief Financial Officer
Ms. Karen Massey	Chief Operating Officer
Dr. Peter Ulrichts	Chief Scientific Officer
Ms. Malini Moorthy	General Counsel
Mr. Arjen Lemmen M.Sc.	Vice President of Corporate Development & Strategy
Ms. Andria Wilk	Global Head of Quality
Dr. Luc Truyen	Chief Medical Officer
Mr. Filip Borgions	Chief Technology Innovation Officer
Ms. Beth DelGiacco	VP and Global Head of Corporate Communications & Investor Relations

Important FAQs about investing in ARGX Stock from India :

What is Argenx Se share price today?

Argenx Se share price today is $704.84 as on August 29, 2025 at 1:29 am IST at the close of the market. Argenx Se share today touched a day high of $704.84 and a low of $698.69.

What is the 52 week high and 52 week low for Argenx Se share?

Argenx Se share touched a 52 week high of $710.00 and a 52 week low of $510.06. Argenx Se stock price today i.e. August 29, 2025 at 1:29 am IST is closed at $704.84, lower by 0.73% versus the 52 week high.

How to invest in Argenx Se Stock (ARGX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Argenx Se on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Argenx Se Shares that will get you 0.0021 shares as per Argenx Se share price of $704.84 per share as on August 29, 2025 at 1:29 am IST.

What is the minimum amount required to buy Argenx Se Stock (ARGX) from India?

Indian investors can start investing in Argenx Se (ARGX) shares with as little as ₹87.6463 or $1 (as of August 29, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹876.46 in Argenx Se stock (as per the Rupee-Dollar exchange rate as on August 29, 2025). Based on Argenx Se share’s latest price of $704.84 as on August 29, 2025 at 1:29 am IST, you will get 0.0142 shares of Argenx Se. Learn more about fractional shares .

What are the returns that Argenx Se has given to Indian investors in the last 5 years?

Argenx Se stock has given 206.12% share price returns and 19.64% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?